论文部分内容阅读
在礼莱 (Ｌｉｌｌｙ)公司的抗抑郁主打药物氟西汀(ｆｌｕｏｘｅｔｉｎｅ ,Ｐｒｏｚａｃ)失去专利保护之后 ,新的资料表明 ,该公司的新型抗抑郁药物度洛西汀 (ｄｕｌｏｘｅｔｉｎｅ)有可能填补此项空白 ,它是一种 5 羟色胺和去甲肾上腺素重摄取抑制剂 (ＳＮＲＩ)。在费城举行的
New data suggest that the company’s new antidepressant drug duloxetine may fill the gap after Lilly’s patent for flu-resistant major drug fluoxetine (Prozac) loses its patent. , A serotonin and norepinephrine reuptake inhibitor (SNRI). Held in Philadelphia